B-cells have been long accepted as the main cellular component in humoral responses. Their effector function is based on antibody and cytokine production. The development of donor-specific antibodies by B-cells has deleterious consequences in graft and patients survival. Recently, a new subset of IL-10-secreting B-cells with regulatory capacity in allergic and autoimmune diseases has been shown. Such regulatory function changes the apprehension of B-cells as effector cells and increases the complexity to the immuno-regulatory networks. New therapies targeting B-cells should consider that depleting B-cells potentially impairs regulatory B-cells (Bregs) and that modulating or favoring the maintenance and function of Bregs would be important for the achievement of humoral tolerance. Unfortunately, few direct pieces of evidence of Breg involvement in allograft tolerance models has been described. Here, we summarize the current knowledge of the role of Bregs in transplantation.
References
[1]
Griffin, D.O.; Rothstein, T.L. A small cd11b(+) human b1 cell subpopulation stimulates t cells and is expanded in lupus. J. Exp. Med. 2011, 208, 2591–2598, doi:10.1084/jem.20110978.
[2]
Yanaba, K.; Bouaziz, J.D.; Matsushita, T.; Tsubata, T.; Tedder, T.F. The development and function of regulatory b cells expressing il-10 (b10 cells) requires antigen receptor diversity and tlr signals. J. Immunol. 2009, 182, 7459–7472, doi:10.4049/jimmunol.0900270.
[3]
Wennhold, K.; Shimabukuro-Vornhagen, A.; Theurich, S.; von Bergwelt-Baildon, M. Cd40-activated b cells as antigen-presenting cells: The final sprint toward clinical application. Expert Rev. Vaccines 2013, 12, 631–637, doi:10.1586/erv.13.39.
[4]
Zhang, X. Regulatory functions of innate-like b cells. Cell. Mol. Immunol. 2013, 10, 113–121, doi:10.1038/cmi.2012.63.
[5]
Goodnow, C.C.; Sprent, J.; Fazekas de St Groth, B.; Vinuesa, C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435, 590–597, doi:10.1038/nature03724.
[6]
Lopes-Carvalho, T.; Kearney, J.F. Development and selection of marginal zone b cells. Immunol. Rev. 2004, 197, 192–205, doi:10.1111/j.0105-2896.2004.0112.x.
[7]
Palanichamy, A.; Barnard, J.; Zheng, B.; Owen, T.; Quach, T.; Wei, C.; Looney, R.J.; Sanz, I.; Anolik, J.H. Novel human transitional b cell populations revealed by b cell depletion therapy. J. Immunol. 2009, 182, 5982–5993, doi:10.4049/jimmunol.0801859.
[8]
Meyer-Bahlburg, A.; Andrews, S.F.; Yu, K.O.; Porcelli, S.A.; Rawlings, D.J. Characterization of a late transitional b cell population highly sensitive to baff-mediated homeostatic proliferation. J. Exp. Med. 2008, 205, 155–168, doi:10.1084/jem.20071088.
[9]
Parsons, R.F.; Vivek, K.; Rostami, S.Y.; Zekavat, G.; Ziaie, S.M.; Luo, Y.; Koeberlein, B.; Redfield, R.R.; Cancro, M.P.; Naji, A.; et al. Acquisition of humoral transplantation tolerance upon de novo emergence of b lymphocytes. J. Immunol. 2011, 186, 614–620, doi:10.4049/jimmunol.1002873.
[10]
Cai, J.; Terasaki, P.I. Humoral theory of transplantation: Mechanism, prevention, and treatment. Hum. Immunol. 2005, 66, 334–342, doi:10.1016/j.humimm.2005.01.021.
[11]
Fidler, S.J.; Irish, A.B.; Lim, W.; Ferrari, P.; Witt, C.S.; Christiansen, F.T. Pre-transplant donor specific anti-hla antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transpl. Immunol. 2013, 28, 148–153, doi:10.1016/j.trim.2013.05.001.
[12]
Lobo, L.J.; Aris, R.M.; Schmitz, J.; Neuringer, I.P. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J. Heart Lung Transplant. 2013, 32, 70–77, doi:10.1016/j.healun.2012.10.007.
[13]
Kaczmarek, I.; Deutsch, M.A.; Kauke, T.; Beiras-Fernandez, A.; Schmoeckel, M.; Vicol, C.; Sodian, R.; Reichart, B.; Spannagl, M.; Ueberfuhr, P. Donor-specific hla alloantibodies: Long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp. Clin. Transplant. 2008, 6, 229–235.
[14]
Detrait, M.; Dubois, V.; Sobh, M.; Morisset, S.; Tedone, N.; Labussiere, H.; Gillis, L.; Barraco, F.; Cannas, G.; Ducastelle, S.; et al. Impact of anti-hla antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens. Exp. Hematol. 2012, 40, 792–799, doi:10.1016/j.exphem.2012.06.003.
[15]
Martinez-Llordella, M.; Puig-Pey, I.; Orlando, G.; Ramoni, M.; Tisone, G.; Rimola, A.; Lerut, J.; Latinne, D.; Margarit, C.; Bilbao, I.; et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transplant. 2007, 7, 309–319, doi:10.1111/j.1600-6143.2006.01621.x.
[16]
Tryphonopoulos, P.; Ruiz, P.; Weppler, D.; Nishida, S.; Levi, D.M.; Moon, J.; Tekin, A.; Velez, M.; Neuman, D.R.; Island, E.; et al. Long-term follow-up of 23 operational tolerant liver transplant recipients. Transplantation 2010, 90, 1556–1561, doi:10.1097/TP.0b013e3182003db7.
[17]
Sagoo, P.; Perucha, E.; Sawitzki, B.; Tomiuk, S.; Stephens, D.A.; Miqueu, P.; Chapman, S.; Craciun, L.; Sergeant, R.; Brouard, S.; et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 2010, 120, 1848–1861, doi:10.1172/JCI39922.
[18]
Newell, K.A.; Asare, A.; Kirk, A.D.; Gisler, T.D.; Bourcier, K.; Suthanthiran, M.; Burlingham, W.J.; Marks, W.H.; Sanz, I.; Lechler, R.I.; et al. Identification of a b cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 2010, 120, 1836–1847, doi:10.1172/JCI39933.
[19]
Patel, R.; Terasaki, P.I. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 1969, 280, 735–739, doi:10.1056/NEJM196904032801401.
[20]
Burns, A.M.; Chong, A.S. Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive t cell priming. J. Immunol. 2011, 186, 214–221, doi:10.4049/jimmunol.1001172.
[21]
Burns, A.M.; Ma, L.; Li, Y.; Yin, D.; Shen, J.; Xu, J.; Chong, A.S. Memory alloreactive b cells and alloantibodies prevent anti-cd154-mediated allograft acceptance. J. Immunol. 2009, 182, 1314–1324.
[22]
Deng, S.; Moore, D.J.; Huang, X.; Lian, M.M.; Mohiuddin, M.; Velededeoglu, E.; Lee, M.K.t.; Sonawane, S.; Kim, J.; Wang, J.; et al. Cutting edge: Transplant tolerance induced by anti-cd45rb requires b lymphocytes. J. Immunol. 2007, 178, 6028–6032.
[23]
Battaglia, M.; Roncarolo, M.G. The role of cytokines (and not only) in inducing and expanding t regulatory type 1 cells. Transplantation 2004, 77, S16–S18, doi:10.1097/01.TP.0000106468.96542.26.
[24]
Fiorentino, D.F.; Bond, M.W.; Mosmann, T.R. Two types of mouse t helper cell. Iv. Th2 clones secrete a factor that inhibits cytokine production by th1 clones. J. Exp. Med. 1989, 170, 2081–2095, doi:10.1084/jem.170.6.2081.
[25]
Gregori, S.; Goudy, K.S.; Roncarolo, M.G. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory t cells. Front. Immunol. 2012, 3, 30.
[26]
Spits, H.; de Waal Malefyt, R. Functional characterization of human il-10. Int Arch. Allergy Immunol. 1992, 99, 8–15, doi:10.1159/000236329.
[27]
de Waal Malefyt, R.; Abrams, J.; Bennett, B.; Figdor, C.G.; de Vries, J.E. Interleukin 10(il-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of il-10 produced by monocytes. J. Exp. Med. 1991, 174, 1209–1220, doi:10.1084/jem.174.5.1209.
[28]
Brooks, D.G.; Walsh, K.B.; Elsaesser, H.; Oldstone, M.B. Il-10 directly suppresses cd4 but not cd8 t cell effector and memory responses following acute viral infection. Proc. Natl. Acad. Sci. USA 2010, 107, 3018–3023.
[29]
Levings, M.K.; Sangregorio, R.; Galbiati, F.; Squadrone, S.; de Waal Malefyt, R.; Roncarolo, M.G. Ifn-alpha and il-10 induce the differentiation of human type 1 t regulatory cells. J. Immunol. 2001, 166, 5530–5539.
[30]
Tilg, H.; van Montfrans, C.; van den Ende, A.; Kaser, A.; van Deventer, S.J.; Schreiber, S.; Gregor, M.; Ludwiczek, O.; Rutgeerts, P.; Gasche, C.; et al. Treatment of crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002, 50, 191–195, doi:10.1136/gut.50.2.191.
[31]
Lauw, F.N.; Pajkrt, D.; Hack, C.E.; Kurimoto, M.; van Deventer, S.J.; van der Poll, T. Proinflammatory effects of il-10 during human endotoxemia. J. Immunol. 2000, 165, 2783–2789.
Zhao, G.; Moore, D.J.; Lee, K.M.; Kim, J.I.; Duff, P.E.; O’Connor, M.R.; Hirohashi, T.; Lei, J.; Yang, M.; Markmann, J.F.; et al. An unexpected counter-regulatory role of il-10 in b-lymphocyte-mediated transplantation tolerance. Am. J. Transplant. 2010, 10, 796–801, doi:10.1111/j.1600-6143.2010.03027.x.
[34]
Tanner, J.E.; Alfieri, C. Epstein-barr virus induces fas (cd95) in t cells and fas ligand in b cells leading to t-cell apoptosis. Blood 1999, 94, 3439–3447.
[35]
Yanaba, K.; Bouaziz, J.D.; Haas, K.M.; Poe, J.C.; Fujimoto, M.; Tedder, T.F. A regulatory b cell subset with a unique cd1dhicd5+ phenotype controls t cell-dependent inflammatory responses. Immunity 2008, 28, 639–650, doi:10.1016/j.immuni.2008.03.017.
[36]
Yang, M.; Sun, L.; Wang, S.; Ko, K.H.; Xu, H.; Zheng, B.J.; Cao, X.; Lu, L. Novel function of b cell-activating factor in the induction of il-10-producing regulatory b cells. J. Immunol. 2010, 184, 3321–3325, doi:10.4049/jimmunol.0902551.
[37]
Ding, Q.; Yeung, M.; Camirand, G.; Zeng, Q.; Akiba, H.; Yagita, H.; Chalasani, G.; Sayegh, M.H.; Najafian, N.; Rothstein, D.M. Regulatory b cells are identified by expression of tim-1 and can be induced through tim-1 ligation to promote tolerance in mice. J. Clin. Invest. 2011, 121, 3645–3656, doi:10.1172/JCI46274.
[38]
Lotz, M.; Ranheim, E.; Kipps, T.J. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia b cells. J. Exp. Med. 1994, 179, 999–1004, doi:10.1084/jem.179.3.999.
[39]
Blair, P.A.; Norena, L.Y.; Flores-Borja, F.; Rawlings, D.J.; Isenberg, D.A.; Ehrenstein, M.R.; Mauri, C. Cd19(+)cd24(hi)cd38(hi) b cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32, 129–140, doi:10.1016/j.immuni.2009.11.009.
[40]
Zha, B.; Wang, L.; Liu, X.; Liu, J.; Chen, Z.; Xu, J.; Sheng, L.; Li, Y.; Chu, Y. Decrease in proportion of cd19+ cd24(hi) cd27+ b cells and impairment of their suppressive function in graves' disease. PLoS One 2012, 7, e49835.
[41]
Lee, J.H.; Noh, J.; Noh, G.; Choi, W.S.; Cho, S.; Lee, S.S. Allergen-specific transforming growth factor-beta-producing cd19+cd5+ regulatory b-cell (br3) responses in human late eczematous allergic reactions to cow's milk. J. Interferon Cytokine Res. 2011, 31, 441–449, doi:10.1089/jir.2010.0020.
[42]
Noh, J.; Choi, W.S.; Noh, G.; Lee, J.H. Presence of foxp3-expressing cd19(+)cd5(+) b cells in human peripheral blood mononuclear cells: Human cd19(+)cd5(+)foxp3(+) regulatory b cell (breg). Immune Netw. 2010, 10, 247–249, doi:10.4110/in.2010.10.6.247.
[43]
Mizoguchi, A.; Mizoguchi, E.; Takedatsu, H.; Blumberg, R.S.; Bhan, A.K. Chronic intestinal inflammatory condition generates il-10-producing regulatory b cell subset characterized by cd1d upregulation. Immunity 2002, 16, 219–230, doi:10.1016/S1074-7613(02)00274-1.
[44]
Matsushita, T.; Yanaba, K.; Bouaziz, J.D.; Fujimoto, M.; Tedder, T.F. Regulatory b cells inhibit eae initiation in mice while other b cells promote disease progression. J. Clin. Invest. 2008, 118, 3420–3430.
[45]
Kitabayashi, A.; Hirokawa, M.; Miura, A.B. The role of interleukin-10 (il-10) in chronic b-lymphocytic leukemia: Il-10 prevents leukemic cells from apoptotic cell death. Int. J. Hematol. 1995, 62, 99–106, doi:10.1016/0925-5710(95)00395-9.
[46]
Natarajan, P.; Singh, A.; McNamara, J.T.; Secor, E.R., Jr.; Guernsey, L.A.; Thrall, R.S.; Schramm, C.M. Regulatory b cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are cd5+, express tgf-beta, and co-localize with cd4+foxp3+ t cells. Mucosal Immunol. 2012, 5, 691–701, doi:10.1038/mi.2012.42.
[47]
Vitale, G.; Mion, F.; Pucillo, C. Regulatory b cells: Evidence, developmental origin and population diversity. Mol. Immunol. 2010, 48, 1–8, doi:10.1016/j.molimm.2010.09.010.
[48]
Chen, W.; Jin, W.; Hardegen, N.; Lei, K.J.; Li, L.; Marinos, N.; McGrady, G.; Wahl, S.M. Conversion of peripheral cd4+cd25- naive t cells to cd4+cd25+ regulatory t cells by tgf-beta induction of transcription factor foxp3. J. Exp. Med. 2003, 198, 1875–1886, doi:10.1084/jem.20030152.
[49]
Marie, J.C.; Letterio, J.J.; Gavin, M.; Rudensky, A.Y. Tgf-beta1 maintains suppressor function and foxp3 expression in cd4+cd25+ regulatory t cells. J. Exp. Med. 2005, 201, 1061–1067, doi:10.1084/jem.20042276.
[50]
Zheng, S.G. Regulatory t cells vs th17: Differentiation of th17 versus treg, are the mutually exclusive? Am. J. Clin. Exp. Immunol. 2013, 2, 94–106.
[51]
Parsons, R.F.; Vivek, K.; Redfield, R.R., 3rd; Migone, T.S.; Cancro, M.P.; Naji, A.; Noorchashm, H. B-lymphocyte homeostasis and blys-directed immunotherapy in transplantation. Transplant. Rev. (Orlando) 2010, 24, 207–221, doi:10.1016/j.trre.2010.05.004.
[52]
Heidt, S.; Hester, J.; Shankar, S.; Friend, P.J.; Wood, K.J. B cell repopulation after alemtuzumab induction-transient increase in transitional b cells and long-term dominance of naive b cells. Am. J. Transplant. 2012, 12, 1784–1792, doi:10.1111/j.1600-6143.2012.04012.x.
[53]
Todeschini, M.; Cortinovis, M.; Perico, N.; Poli, F.; Innocente, A.; Cavinato, R.A.; Gotti, E.; Ruggenenti, P.; Gaspari, F.; Noris, M.; et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces b cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-hla antibody development. J. Immunol. 2013, 191, 2818–2828, doi:10.4049/jimmunol.1203261.
[54]
Parsons, R.F.; Vivek, K.; Redfield, R.R.; Migone, T.S.; Cancro, M.P.; Naji, A.; Noorchashm, H. B-cell tolerance in transplantation: Is repertoire remodeling the answer? Expert Rev. Clin. Immunol. 2009, 5, 703–723, doi:10.1586/eci.09.63.
